Thryv is a private clinical-stage biopharmaceutical company based in Montreal, Quebec. The company is developing first-in-class treatments for cardiovascular diseases. The company's lead asset is being studied in Phase 2 clinical study for the treatment of the genetic forms of Long QT syndrome.
Pediatric cardiovascular disorders
CTI LSF III
Syndicate
Observer
January 11, 2024
Active
Series A
Thryv has a first-in-class treatment for a rare pediatric cardiology disease called Long QT Syndrome that demonstrated strong efficacy signal in its Phase 2a study
